相似文献
1
Emerging Therapeutic Options for the Management of COPD.
Clin Med Insights Circ Respir Pulm Med. 2013 Apr 9;7:7-15. doi: 10.4137/CCRPM.S8140. Print 2013.
2
Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Int J Chron Obstruct Pulmon Dis. 2012;7:375-82. doi: 10.2147/COPD.S31100. Epub 2012 Jun 20.
3
Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ther Adv Respir Dis. 2015 Apr;9(2):49-55. doi: 10.1177/1753465815572065. Epub 2015 Feb 17.
4
Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
Prescrire Int. 2016 Nov;25(176):272-277.
5
Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium.
Multidiscip Respir Med. 2014 Dec 8;9(1):64. doi: 10.1186/2049-6958-9-64. eCollection 2014.
6
Long-acting muscarinic antagonists.
Expert Rev Clin Pharmacol. 2015;8(4):479-501. doi: 10.1586/17512433.2015.1058154.
7
Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
Pulm Pharmacol Ther. 2017 Aug;45:19-33. doi: 10.1016/j.pupt.2017.04.002. Epub 2017 Apr 4.
8
Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
Int J Chron Obstruct Pulmon Dis. 2015 Jul 23;10:1383-92. doi: 10.2147/COPD.S55488. eCollection 2015.
9
Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
Lancet Respir Med. 2018 May;6(5):368-378. doi: 10.1016/S2213-2600(18)30054-7. Epub 2018 Feb 21.
10
Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD.
Curr Med Chem. 2013;20(12):1464-76. doi: 10.2174/0929867311320120002.
引用本文的文献
1
Machine-Learning Algorithm-Based Prediction of Diagnostic Gene Biomarkers Related to Immune Infiltration in Patients With Chronic Obstructive Pulmonary Disease.
Front Immunol. 2022 Mar 8;13:740513. doi: 10.3389/fimmu.2022.740513. eCollection 2022.
2
Preparation of Curcumin Solid Lipid Nanoparticles Loaded with Flower-Shaped Lactose for Lung Inhalation and Preliminary Evaluation of Cytotoxicity In Vitro.
Evid Based Complement Alternat Med. 2021 Oct 28;2021:4828169. doi: 10.1155/2021/4828169. eCollection 2021.
3
The Prediction of miRNAs in SARS-CoV-2 Genomes: hsa-miR Databases Identify 7 Key miRs Linked to Host Responses and Virus Pathogenicity-Related KEGG Pathways Significant for Comorbidities.
Viruses. 2020 Jun 4;12(6):614. doi: 10.3390/v12060614.
4
Overexpression Of hsa-miR-664a-3p Is Associated With Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease Via Targeting FHL1.
Int J Chron Obstruct Pulmon Dis. 2019 Oct 9;14:2319-2329. doi: 10.2147/COPD.S224763. eCollection 2019.
5
Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease.
Ther Clin Risk Manag. 2014 Jun 13;10:449-53. doi: 10.2147/TCRM.S39710. eCollection 2014.
本文引用的文献
1
Novel antiinflammatory therapies for COPD.
Chest. 2012 Nov;142(5):1300-1307. doi: 10.1378/chest.11-2766.
2
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.
Eur Respir J. 2012 Nov;40(5):1106-14. doi: 10.1183/09031936.00040712. Epub 2012 Jul 26.
3
Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit.
Int J Chron Obstruct Pulmon Dis. 2012;7:673-8. doi: 10.2147/COPD.S35990. Epub 2012 Sep 26.
4
Chronic obstructive pulmonary disease: a worldwide problem.
Med Clin North Am. 2012 Jul;96(4):671-80. doi: 10.1016/j.mcna.2012.02.005.
5
Pharmacology and therapeutics of bronchodilators.
Pharmacol Rev. 2012 Jul;64(3):450-504. doi: 10.1124/pr.111.004580. Epub 2012 May 18.
6
Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.
Thorax. 2012 Sep;67(9):781-8. doi: 10.1136/thoraxjnl-2011-201140. Epub 2012 Apr 27.
7
Indacaterol: a novel long-acting β(2) -agonist.
Pharmacotherapy. 2012 May;32(5):456-74. doi: 10.1002/j.1875-9114.2012.01025.x. Epub 2012 Apr 12.
8
A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.
Pulm Pharmacol Ther. 2012 Jun;25(3):248-53. doi: 10.1016/j.pupt.2012.03.008. Epub 2012 Apr 4.
9
New bronchodilators.
Curr Opin Pharmacol. 2012 Jun;12(3):238-45. doi: 10.1016/j.coph.2012.02.019. Epub 2012 Mar 21.
10
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
Eur Respir J. 2012 Oct;40(4):830-6. doi: 10.1183/09031936.00225511. Epub 2012 Mar 22.
Zotero 插件